{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:23:32Z","timestamp":1790810612183,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312\"","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312\"","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across studies, test\u2013retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity\u2013Atopic Dermatitis (PGI-S-AD), 0\u00b7516\u20130\u00b7639; for Eczema Area and Severity Index (EASI), 0\u00b7658\u20130\u00b7778]. Moderate-to-large correlations between vIGA-AD and EASI or body surface area (range at baseline, 0\u00b7497\u20130\u00b7736; Week 16, 0\u00b7716\u20130\u00b7893) supported convergent validity. Known-groups validity was demonstrated vs. EASI and PGI-S-AD (vIGA-AD for severe vs. moderate EASI categories at baseline, P &amp;lt; 0\u00b7001). Responsiveness was demonstrated vs. EASI (P &amp;lt; 0\u00b7001 for much improved vs. improved and improved vs. stable). Anchor- and distribution-based methods supported a vIGA-AD change of \u20131\u00b70 as clinically meaningful. These findings are limited to populations defined by the studies\u2019 inclusion and exclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The vIGA-AD demonstrated sufficient reliability, validity, responsiveness and interpretation standards for use in clinical trials.<\/jats:p>\n                    <jats:p>What is already known about this topic? \u00a0A description of the development of the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122) has been published previously.<\/jats:p>\n                    <jats:p>What does this study add? \u00a0The current study validates the vIGA-AD by demonstrating appropriate test\u2013retest reliability, convergent validity, known-groups validity and responsiveness across three baricitinib clinical studies.In addition, a 1-point change was identified as a clinically meaningful patient-perceived change minimal clinically important difference in the vIGA-AD.<\/jats:p>\n                    <jats:p>What are the clinical implications of the work? \u00a0The vIGA-AD is a measure for investigator assessment of atopic dermatitis suitable for use in clinical research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bjd.21615","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T10:28:01Z","timestamp":1650450481000},"page":"531-538","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD\u2122): a clinical outcome measure for the severity of atopic dermatitis"],"prefix":"10.1093","volume":"187","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[{"name":"Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc., Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"additional","affiliation":[{"name":"Yale School of Medicine New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg-Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bispebjerg Hospital University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Doll","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Solutions, Folkestone UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Sun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"DeLozier","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio P.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC, PA; this work performed previously while at Eli Lilly and Company Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"2023010808115066800_bjd21615-bib-0001","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"2023010808115066800_bjd21615-bib-0002","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023010808115066800_bjd21615-bib-0003","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaci.2007.08.011","article-title":"What are the best outcome measurements for atopic eczema? A systematic review","volume":"120","author":"Schmitt","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2023010808115066800_bjd21615-bib-0004","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2023010808115066800_bjd21615-bib-0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"EASI Evaluator Group. Exp Dermatol"},{"issue":"23\u201331","key":"2023010808115066800_bjd21615-bib-0006","article-title":"[No authors listed]. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis","volume":"186","year":"1993","journal-title":"Dermatology"},{"key":"2023010808115066800_bjd21615-bib-0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0009","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"2023010808115066800_bjd21615-bib-0012","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychol Bull"},{"key":"2023010808115066800_bjd21615-bib-0013","volume-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"key":"2023010808115066800_bjd21615-bib-0014","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd edn"},{"key":"2023010808115066800_bjd21615-bib-0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika"},{"key":"2023010808115066800_bjd21615-bib-0016","first-page":"248","volume-title":"Psychometric Theory","author":"Nunnally","year":"1994"},{"key":"2023010808115066800_bjd21615-bib-0017","doi-asserted-by":"crossref","DOI":"10.4135\/9781483348957","volume-title":"How to Measure Survey Reliability and Validity","author":"Litwin","year":"1995"},{"key":"2023010808115066800_bjd21615-bib-0018","volume-title":"Tucson","author":"Clinical Outcomes Solutions. Outcomes Psychometric Summit: Consensus Panel. C-Path PRO Consortium Partner-led Meeting","year":"2015"},{"key":"2023010808115066800_bjd21615-bib-0019","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/bjd.13662","article-title":"What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study","volume":"172","author":"Leshem","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2023010808115066800_bjd21615-bib-0021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023010808115066800_bjd21615-bib-0022","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaad.2020.01.023","article-title":"Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children","volume":"82","author":"Suh","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/531\/48529749\/bjd0531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/4\/531\/48529749\/bjd0531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:12:50Z","timestamp":1676365970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/4\/531\/6966327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21615","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"2021-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}